Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.
Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.
Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.
Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.
Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.
Hologic, Inc. (NASDAQ: HOLX) recently announced FDA approval for its Aptima CMV Quant assay, the first quantitative test for monitoring cytomegalovirus (CMV) in solid organ and stem cell transplant patients. This innovative test enhances patient outcomes by providing standardized clinical information and is fully automated on the Panther® system. With existing capabilities for viral load testing in HIV-1 and Hepatitis, Hologic aims to improve the management of transplant patients susceptible to infections. Future assays for BK Virus and Epstein-Barr Virus are in development.
Hologic, Inc. (NASDAQ: HOLX) will be participating in two key investor conferences. The Bank of America 2022 Healthcare Conference is scheduled for May 10 at 8:00 a.m. Pacific Time, while the William Blair 42nd Annual Growth Stock Conference is set for June 7 at 2:00 p.m. Central Time. Both presentations will be available via live webcast on Hologic's investor website, accessible for 30 days post-event. Hologic focuses on advancing women’s health through innovative medical technologies.
Hologic reported Q2 fiscal 2022 revenue of $1.436 billion, a 6.6% decline compared to the previous year, primarily due to lower COVID-19 assay sales. However, this figure exceeded the company's guidance of $1.25 to $1.3 billion. GAAP diluted EPS was $1.80, down 24.4% year-over-year, with non-GAAP diluted EPS at $2.07. Despite declines in various segments, the company raised its full-year revenue and EPS guidance, reflecting strong cash flow from operations of $1.062 billion and a robust balance sheet.
Hologic announces that the American Society of Clinical Oncology (ASCO) has updated its guidelines to include Breast Cancer Index™ (BCI) as the only genomic test for determining extended endocrine therapy in early-stage, HR+ breast cancer patients. This guideline aims to help healthcare providers make informed treatment decisions after five years of primary therapy. BCI is recognized for its ability to predict which patients may benefit from continued treatment, mitigating unnecessary side effects associated with extended therapy.
Hologic, Inc. (Nasdaq: HOLX) has announced the release of its second-quarter fiscal 2022 financial results, scheduled for April 27, after market close. A conference call will follow at 4:30 p.m. Eastern Time for discussion of the results. Participants can join by dialing specific numbers or click here to join. A replay will be available post-call until May 27, 2022.
Hologic, Inc. (NASDAQ: HOLX) has launched a new Innovation Center in Aix-en-Provence, France, marking a significant expansion of its commitment to women's health. This facility, which serves as the new French headquarters, will focus on ultrasound, interventional, and surgical solutions in breast health care. Following the acquisition of SuperSonic Imagine in 2019, Hologic aims to enhance access to innovative healthcare technologies in the EMEA region. The investment reflects Hologic's mission to improve the health of 3.9 billion women worldwide.
Hologic has partnered with the WTA to enhance women’s health and wellness through advanced screening technologies, starting at the BNP Paribas Open in Indian Wells. The collaboration includes providing athletes with access to Hologic’s Horizon® DXA system for detailed body composition and bone health analysis. Alongside enhanced screenings, Hologic will support the ACEing Cancer program, aimed at raising awareness and funds for women’s cancers. This partnership aims to prioritize women's health and addresses the decline in health screenings due to the COVID pandemic.
Hologic has announced a landmark multi-year partnership with the WTA, becoming the official health partner and global title sponsor of the WTA Tour. This represents the largest global sponsorship in WTA history and marks Hologic’s first worldwide sponsorship. The collaboration aims to promote women’s health and equality through initiatives that emphasize preventive care and healthy living. Hologic, known for its innovations in women’s health, will also support the creation of Hologic WTA Labs, focusing on health innovation for female athletes.
Hologic, Inc. (Nasdaq: HOLX) has announced its upcoming participation in two significant investor conferences. The first is Citi's 2022 Healthcare Services, Medtech, Tools & HCIT Virtual Conference scheduled for February 23 at 1:15 p.m. ET. The second is The Raymond James Institutional Investors Conference on March 8 at 9:50 a.m. ET. Both presentations will be webcast live and available for 30 days on Hologic's investor website.
Hologic focuses on enhancing women's health through early detection and treatment solutions.
Hologic (HOLX) reported Q1 2022 revenue of $1.471 billion, down 8.6% year-over-year, notably exceeding prior guidance of $1.1-$1.15 billion. GAAP diluted EPS was $1.95 while non-GAAP diluted EPS was $2.17, both below last year's figures. Organic revenue grew 9% excluding COVID sales, with Breast Health and GYN Surgical divisions each above 8% growth. The company significantly raised its full-year revenue guidance by $600 million and non-GAAP EPS by $1.35. Cash flow from operations remained robust at $564.2 million.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
What does Hologic Inc. specialize in?
Where is Hologic Inc. headquartered?
What are the main segments of Hologic’s business?
Which segment contributes the most to Hologic's revenue?
How has the pandemic affected Hologic’s business segments?
What percentage of Hologic’s revenue comes from the United States?
How did the acquisition of Gen-Probe impact Hologic?
How can I stay updated with Hologic's latest news?
What is Hologic’s approach to healthcare?
What percentage of Hologic’s revenue comes from international markets?
